Delivery Order SPE2DB24D3015-SPE2DB25FGAED
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 30 mg capsules (100-count) with a contract value of $2,117.56 and completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $2,675.40. This competitively awarded, firm fixed-price delivery order is set to be completed by July 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 10 mg capsules (100 count) with a contract value of $1,783.60. This firm fixed-price delivery order, which represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle, is scheduled for completion by July 30, 2025. The award carries no set-aside designation, indicating it was competitively awarded. Performance will be executed from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Vyvanse 10 mg capsules (100 count) with a contract value of $2,100.43. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX valued at $999,999,999.00 through December 2026). The ultimate completion date is scheduled for August 14, 2025,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $2,079.25. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Vyvanse 50 mg capsules (100-count) under a firm fixed-price contract with a ceiling value of $5,192.54. The order, which is classified as a child contract under a larger indefinite delivery vehicle, carries an ultimate completion date of July 24, 2025. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a contract ceiling value of $3,071.84. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Vyvanse capsules 70mg, with a ceiling value of $9,638.76. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's competitive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $13,200.69. This is a competitively awarded, non-set-aside delivery order with an ultimate completion date of July 31, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGAEDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Vyvanse 10 mg capsules (100-count units) with a contract ceiling value of $1,333.84. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and carries no set-aside designation, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999.00 prime vendor agreement valued through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen serves as a critical pharmaceutical distributor for federal medical procurement, with extensive experience fulfilling DLA requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and related medical supplies for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 7/18/25 |